Publications

Impact of Metformin, Statin, Aspirin and Insulin on the Prognosis of Unresectable Hcc Patients Receiving First-Line Lenvatinib or Atezolizumab plus Bevacizumab

AuthID
P-00Z-QR4

Author(s)

Rimini, M

Amadeo, E

Vitiello, F

Foti, S

Persano, M

Tada, T

Suda, G

Shimose, S

Kudo, M

Cheon, J

Finkelmeier, F

Lim, HY

Piscaglia, F

Masi, G

Yoo, C

Lonardi, S

Rossari, F

Camera, S

Gardini, AC

Presa, J

Document Type

Abstract

Year published

2023

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 34, Pages: S1548-S1548 (1)

Conference

Annual Meeting of the European-Society-For-Medical-Oncology (Esmo), Date: DEC 01-03, 2023, Location: SINGAPORE

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2023.10.767

Wos: WOS:001122475400191

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Impact of Metformin, Statin, Aspirin and Insulin on the Prognosis of Unresectable Hcc Patients Receiving First-Line Lenvatinib or Atezolizumab plus Bevacizumab

Useful Links

Get Help

Federated Authentication (Click on the image)

Impact of Metformin, Statin, Aspirin and Insulin on the Prognosis of Unresectable Hcc Patients Receiving First-Line Lenvatinib or Atezolizumab plus Bevacizumab

Useful Links

Get Help